Bavarian Nordic (BVNRY) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Bavarian Nordic (OTCMKTS:BVNRY) from a hold rating to a sell rating in a report published on Wednesday morning.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Separately, Maxim Group cut shares of Bavarian Nordic from a buy rating to a hold rating in a report on Friday, September 15th.

Bavarian Nordic (OTCMKTS BVNRY) opened at $12.72 on Wednesday. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1,221.61, a P/E ratio of 35.33 and a beta of -5.08. Bavarian Nordic has a twelve month low of $10.57 and a twelve month high of $22.70.

COPYRIGHT VIOLATION WARNING: “Bavarian Nordic (BVNRY) Rating Lowered to Sell at Zacks Investment Research” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/03/bavarian-nordic-bvnry-rating-lowered-to-sell-at-zacks-investment-research.html.

Bavarian Nordic Company Profile

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Get a free copy of the Zacks research report on Bavarian Nordic (BVNRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Bavarian Nordic? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bavarian Nordic and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit